Ramoplanin: A topical lipoglycodepsipeptide antibacterial agent

Expert Review of Anti-Infective Therapy

Volumn 4, Issue 6, 2006, Pages 939-945

  Fulco, Patricia ^a   Wenzel, Richard P ^b  

^a VIRGINIA COMMONWEALTH UNIVERSITY MEDICAL CENTER   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antibiotic resistance; Clostridium difficile; Gram positive bacteria; Ramoplanin; Vancomycin resistant enterococci

Indexed keywords

CLINDAMYCIN; COTRIMOXAZOLE; DOXYCYCLINE; GENTAMICIN; PEPTIDOGLYCAN; PLACEBO; POLYPEPTIDE ANTIBIOTIC AGENT; RAMOPLANIN; VANCOMYCIN;

ABDOMINAL PAIN; ACUTE KIDNEY FAILURE; AEROBIC BACTERIUM; ANAEROBIC BACTERIUM; ANEMIA; ANGINA PECTORIS; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; AORTA STENOSIS; ARTICLE; BACTERIAL CELL; CHOLELITHIASIS; CLINICAL TRIAL; CLOSTRIDIUM DIFFICILE; COLITIS; DEEP VEIN THROMBOSIS; DIARRHEA; DISEASE SEVERITY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG COST; DRUG EFFICACY; DRUG INDICATION; DRUG MARKETING; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; DYSPEPSIA; ENTEROCOCCAL INFECTION; ENTEROCOCCUS; FLATULENCE; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SYMPTOM; GASTROINTESTINAL TRACT; GRAM POSITIVE BACTERIUM; HUMAN; HYPOXIA; ILEUS; MINIMUM INHIBITORY CONCENTRATION; MUCOSA INFLAMMATION; NAUSEA; PANCREATITIS; PHARMACODYNAMICS; PROCTITIS; RESPIRATORY FAILURE; SEPSIS; SINGLE DRUG DOSE; SMALL INTESTINE OBSTRUCTION; STRUCTURE ANALYSIS; UNITED STATES; VOMITING;

ADMINISTRATION, TOPICAL; ANTI-BACTERIAL AGENTS; CELL WALL; CLOSTRIDIUM DIFFICILE; DEPSIPEPTIDES; ENTEROCOLITIS; HUMANS; PEPTIDOGLYCAN;

EID: 33846018033     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/14787210.4.6.939     Document Type: Article

References (36)

1. Edmond MB, Wallace SE, McClish DK, Pfaller MA, Jones RN, Wenzel RP. Nosocomial bloodstream infections in United States hospitals: a three-year analysis. Clin. Infect. Dis. 29, 239-244 (1999).
2. Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Edmond MB. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin. Infect. Dis. 39, 309-317 (2004).
3. Wenzel RP. Attributable mortality: the promise of better antimicrobial therapy. J. Infect. Dis. 178, 917-919 (1998).
4. Farver DK, Hedge DD, Lee SC. Ramoplanin: a lipoglycodepsipetide antibiotic. Ann. Pharmacother. 39, 863-868 (2005).
5. Walker S, Chen L, Hu Y, Rew Y, Shin D, Boger DL. Chemistry and biology of ramoplanin: a lipo-glycodepsipeptide with potent antibiotic activity. Chem. Rev. 105, 449-475 (2005).
6. Montecalvo MA. Ramoplanin: a novel antimicrobial agent with the potential to prevent vancomycin-resistant enterococcal infection in high-risk patients. J. Antimicrob. Chemother. 51(S3), 31-35 (2003).
7. Cavalleri B, Pagani H, Volpe G, Selva E, Parenti F. A-16686, a new antibiotic from actinoplanes. I. Fermentation, isolation and preliminary physico-chemical characteristics. J. Antibiotic. 37, 309-317 (1984).
8. Pittet D, Davis CS, Li N, Wenzel RP. Identifying the hospitalized patient at risk for nosocomial bloodstream infection: a population-based study. Proc. Assoc. Am. Physicians 109, 58-67 (1997).
9. Davey P, Brown E, Fenelon L et al. Systematic review of antimicrobial drug prescribing in hospitals. Emerg. Infect. Dis. 12, 211-216 (2006).
10. Kreman T, Hu J, Pottinger J, Herwaldt LA. Survey of long-term facilities in Iowa policies and practices regarding patients with methicillin-resistant Staphylococcus aureus or vancomycin-resistant enterococci. Infect. Control Hosp. Epidemiol. 26, 811-815 (2005).
11. Mody L, Kauffman CA, McNeil SA, Galecki AT, Bradley SF. Mupirocin-based decolonization of Staphylococcus aureus carriers in residents of 2 long-term care facilities: a randomized, double-blind, placebo-controlled trial. Clin. Infect. Dis. 37, 1467-1474 (2003).
12. Simor AE, Bradley SF, Strausbaugh LJ, Crossley K, Nicolle LE; SHEA Long-Term-Care Committee. Clostridium difficile in long term-care facilities for the elderly. Infect. Control Hosp. Epidemiol. 23, 696-703 (2003).
13. Kluytmans-Vandenbergh MF, Kluytmans JA. Community-acquired methicillin-resistant Staphylococcus aureus: current perspectives. Clin. Microbiol. Infect. 12(Suppl. 1), 9-15 (2006).
14. Rybak MJ, LaPlante KL. Community-associated methicillin-resistant Staphylococcus aureus: a review. Pharmacotherapy 25, 74-85 (2005).
15. Genestier AL, Michallet MC, Prevost G et al. Staphylococcus aureus Panton-Valentine leukocidin directly targets mitochondria and induces Bax-dependent apoptosis of human neutrophils. J. Clin. Invest. 115, 3117-3127 (2005).
16. Jiang W, Wanner J, Lee RJ, Bounaud PY, Boger DL. Total synthesis of the ramoplanin A2 and ramoplanose aglycon. J. Am. Chem. Soc. 125, 1877-1887 (2003).
17. Pallanza R, Berti M, Scotti R, Randisi E, Arioli V. A-16686, a new antibiotic from actinoplanes. II. Biological properties. J. Antibiotic. 37, 318-324 (1984).
18. Ciabatti R, Kettenring JK, Winters G, Tuan G, Zerilli L, Cavalleri B. Ramoplanin (A-16686), a new glycolipodepsipeptide antibiotic. III. Structure elucidation. J. Antibiotic. 42, 254-67 (1989).
19. Somner EA, Reynolds PE. Inhibition of peptidoglycan biosynthesis by ramoplanin. Antimicrob. Agents Chemother. 34, 413-419 (1990).
20. Reynolds PE, Somner EA. Comparison of the target sites and mechanisms of action of glycopeptide and lipoglycodepsipeptide antibiotics. Drugs Exptl Clin. Res. 16, 385-390 (1990).
21. Lo MC, Men H, Branstrom A et al. A new mechanism of action proposed for ramoplanin. J. Am. Chem. Soc. 122, 3540-3541 (2000).
22. Hu Y, Helm JS, Chen L, Ye XY, Walker S. Ramoplanin inhibits bacterial transglycosylases by binding as a dimer to Lipid II. J. Am. Chem. Soc. 125, 8736-8737 (2003).
23. Ha S, Walker D, Shi Y, Walker S. The 1.9 A crystal structure of Escherichia coli MurG, membrane-associated glycosyltransferase involved in peptidoglycan biosynthesis. Protein Sci. 9, 1045-1052 (2000).
24. Chen L, Yuan Y, Helm JS et al. Dissecting ramoplanin: mechanistic analysis of synthetic ramoplanin analogues as a guide to the design of improved antibiotics. J. Am. Chem. Soc. 126, 7462-7463 (2004).
25. Shin D, Rew Y, Boger DL. Total synthesis and structure of the ramoplanin A1 and A3 aglycons: two minor components of the ramoplanin complex. Proc. Natl Acad. Sci. USA 101, 11977-11979 (2004).
26. Ling LL, Fan J, Schumacher T, Borsari B, Davey M, Puyang X. Over-expression of murG in S. aureus does not alter the ramoplanin MIC (Abstracts). Presented at: 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy. IL, USA, 14-17 September (2003).
27. Goossens H, Jabes D, Rossi R et al. European survey of Vancomycin-resistant enterococci in at-risk hospital wards and in vitro susceptibility testing of ramoplanin against these isolates. J. Antimicrob. Chemother. 51(Suppl. 3) 5-12 (2003).
28. Mobarakai N, Quale JM, Landman D. Bactericidal activities of peptide antibiotics against multi drug-resistant Entercoccus faecium. Antimicrob. Agents Chemother. 38, 385-387 (1994).
29. Pelaez T, Alcala A, Alonso R et al. In vitro activity of ramoplanin against Clostridium difficile, including strains with reduced susceptibility to vancomycin or with resistance to metronidazole. Antimicrob. Agents Chemother. 49, 1157-1159 (2005).
30. Citron DM, Merriam CV, Tyrrell KL et al. In vitro activities of ramoplanin, teicoplanin, vancomycin, linezolid, bacitracin and four other antimicrobials against international aerobic bacteria. Antimicrob. Agents Chemother. 47, 2334-2338 (2003).
31. de Lalla F, Romeo B, Nicolin R, Pallizzer G, Merati R, Riva E. Oral ramoplanin (R) single-dose administration in pseudomembranous colitis (PMC). Can. J. Infect. Dis. 6(Suppl. 5), 452C (1995).
32. Romeo B, Kaschub M, Cavenaghi L et al. Repeated doses of ramoplanin orally administered to healthy and male volunteers: tolerability, lack of absorption and effect on the stool microflora (Abstracts). Presented at: 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy DC, USA (1993).
33. Wong MT, Kauffman CA, Standiford HC et al. Effective suppression of vancomycin-resistant enterococci species in asymptomatic gastrointestinal carriers by a novel glycolipodespsipeptide, ramoplanin. Clin. Infect. Dis. 33, 1476-1482 (2001).
34. Pullman J, Prieto J, Leach TS. Ramoplanin vs. vancomycin in the treatment of Clostridium difficile diarrhea: a Phase II study (Abstracts). Presented at: 44th Interscience Conference on Antimicrobial Agents and Chemotherapy DC, USA, 30 October-2 November (2004).
35. Bricker E, Garg R, Nelson R et al. Antibiotic treatment for Clostridium difficile-associated diarrhea in adults. Cochrane Database Syst. Rev. 25(1), CD004610 (2005).
36. Loo VG, Poirer L, Miller M et al. A predominately clonal multi-institutional outbreak of Clostridium difficile associated diarrhea with high morbidity and mortality. N. Engl. J. Med. 353, 2442-2449 (2005).